ASCO 2018 | FORTE update: carfilzomib-lenalidomide induction therapy for MM

Francesca Gay

Francesca Gay, MD, of the University of Torino, Torino, Italy, provides an efficacy data update from the FORTE trial (NCT02203643), which investigated carfilzomib plus lenalidomide or cyclophosphamide for the treatment of newly diagnosed multiple myeloma (MM) prior to transplant. She highlights complete response rates with both regimens, as well as the results of MRD analysis. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video